Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement Authors
First Online: 27 July 2010 Received: 16 June 2010 Accepted: 19 June 2010 DOI:
Cite this article as: Pienkowska-Grela, B., Rymkiewicz, G., Grygalewicz, B. et al. Med Oncol (2011) 28: 1589. doi:10.1007/s12032-010-9614-0 Abstract
Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of
MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas. Keywords Non-Hodgkin’s lymphoma Burkitt morphology Chromosome aberrations FISH References
Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.
Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6.
Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4.
Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.
Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.
Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.
Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11.
Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4.
Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.
Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.
Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.
Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program.
Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.
Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005.
Mitelman Database of Chromosome Aberrations in Cancer, The Cancer Genome Anatomy Project
. Accessed 14 July 2009.
Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.
Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.
Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.
Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.
Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.
PubMed Copyright information
© Springer Science+Business Media, LLC 2010